Rx00182 - Paromomycin


Name:
Paromomycin
Rx ID:
Rx00182
Validation Level:
Phenomic Similarity:
0.54
Reference ID:
DB01421
Primary Indications:
Acute intestinal amebiasis; chronic intestinal amebiasis; hepatic coma
Orphan Indications:
Tuberculosis; Mycobacterium avium complex; visceral leishmaniasis; kala-azar
Rare Indications:
Acute intestinal amebiasis; chronic intestinal amebiasis
Common Indications:
Hepatic coma
Drug Interactions:
No annotated drug interactions in DrugBank.
Food Interactions:
Take with food.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00182
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
acute intestinal amebiasis chronic intestinal amebiasis 13 13 13 310378.769 8.96E-63 2.88e-59
chronic intestinal amebiasis acute intestinal amebiasis 13 13 13 310378.769 8.96E-63 2.88e-59
hepatic coma tuberculosis 12 1472 1835 17.926 9.94E-12 3.19e-08

Chemical, Pharmacological and Biological Annotations


ATC Code:
A07AA06
Brand:
Humatin (Parke Davis (now Pfizer))
Categories:
Anti-Bacterial Agents; Amebicides
PubChem ID:
165580
SMILE:
NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
InChI:
1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Organooxygen Compounds
Class:
Carbohydrates and Carbohydrate Conjugates
Subclass:
Amino Sugars
Indication:
For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.
Pharmacodynamics:
Paromomycin is a broad spectrum aminoglycoside antibiotic produced by <i>Streptomyces rimosus</i> var. paromomycinus. The in vitro and in vivo antibacterial action of paromomycin closely parallels that of neomycin.
Description:
An oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Mechanism:
Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA. Bacterial proteins are synthesized by ribosomal RNA complexes which are composed of 2 subunits, a large subunit (50s) and small (30s) subunit, which forms a 70s ribosom...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
-
Blood Brain Barrier:
-
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
1.4850 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org